You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases

    SBC: BIOSTRATAGIES LC            Topic: NICHD

    Mucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, musculoskeletal, and central nervous systems leading to devastating quality-of-life and early death. The disease is due to deficiencies in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) causing progre ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. 3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection

    SBC: SINTX TECHNOLOGIES, INC.            Topic: NIAMS

    PROJECT SUMMARYSpinal fusion is the standard treatment for persistent neck and back pain, but the hardware used to stabilize the fusion can harbor or even promote bacteria that lead to persistent, difficult-to-treat infections that are costly and damaging to patient health. Among the available materials for spinal fusion, polyether-ether-ketone (PEEK) cages stand out due to their strength, biocomp ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis

    SBC: D BioTherapeutics, LLC            Topic: NIAMS

    Rheumatoid arthritis (RA) is a chronic, debilitating inflammatory disease with high medical and societal costs afflicting more than 1.6 million Americans. Blockade of TNFα-driven inflammation with approved anti-TNFα biologics (such as Humira®, Remicade®, Simponi®, and Enbrel®) is an effective treatment for many patients suffering from RA. However, due at least in part to the immunogenicity o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases

    SBC: Nephropathology Associates, PLC            Topic: 400

    Project Summary The goal of this Direct to Phase II program is to develop and test the efficacy of a Precision Medicine Clinical Trials Enrollment Platform for kidney diseases. Approximately half of randomized controlled trials do not meet their recruiting target. Enrolling trials targeting rare kidney diseases is particularly challenging with many conditions subject to stratification and sub-typi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Commercial translation of high-density carbon fiber electrode arrays for multi-modal analysis of neural microcircuits

    SBC: BLACKROCK MICROSYSTEMS, INC            Topic: 106

    ABSTRACT The ability to measure and manipulate local brain circuit activity in living, behaving animals is essential to understanding the complexities of brain function and dysfunction. A novel, penetrating high-density carbon fiber electrode array composed of flexible, ultrathin conductive carbon microfibers was recently developed under the BRAIN Initiative to study neural microcircuit dynamics. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. CUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERS

    SBC: Proactive Memory Services            Topic: R

    CUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERSProject Summary/Abstract - ProActive Memory Services, Inc. New strategies are urgently needed to improve Alzheimer’s disease and related dementias (AD/RD) training for 4.6 million professional direct care providers that assist 8.3 million older adults in the US. Assisted living facilities (ALF) and personal care agenc ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)

    SBC: BIOSTRATAGIES LC            Topic: 105

    PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo A syndrome). In contrast to other gene therapies in development for MPS IIIA, BioStrategies’ approach is designed to achieve a systemic therapeutic effect, including delivery of a functiona ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility

    SBC: INHERENT BIOSCIENCES, INC.            Topic: NICHD

    NIH SBIR Fast-Track Application: Inherent Biosciences SUMMARY/ABSTRACT Title: Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility39.7 million men worldwide (1% of the male population) suffer the severest form of male infertility: Non-Obstructive Azoospermia (NOA). These men have no identifiable sperm in their semen, greatly limiti ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government